Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of IMO 9200 in volunteers

Trial Profile

Phase I trial of IMO 9200 in volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMO 9200 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 18 May 2015 Results published in the Idera Pharmaceuticals Media Release.
    • 18 May 2015 Status changed from recruiting to completed, according to an Idera Pharmaceuticals media release.
    • 07 Nov 2014 Idera Pharmaceuticals expects to select a lead autoimmune disease indication for further development of IMO-9200 in the first half of 2015, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top